Top

Open Access 24-04-2024 | Osteoporosis | Original Article

Treatment patterns in women with postmenopausal osteoporosis using abaloparatide: a real-world observational study

Authors: Deborah T. Gold, Tammy Beckett, Chad Deal, Andrew L. James, Mahshid Mohseni, Abigail McMillan, Tom Bailey, Leny Pearman, John Caminis, Yamei Wang, Setareh A. Williams, Jacqueline M. Kernaghan

Published in: Osteoporosis International

Abstract

Summary

Review of medical records from 173 women with osteoporosis who received abaloparatide treatment revealed that 96.0% had at least one visit for osteoporosis management and 55.5% had medication support group access. The most common reasons for discontinuing treatment were financial (31.2%) and tolerability (22.8%). Most patients (64.8%) completed treatment as prescribed.

Purpose

Abaloparatide is approved for the treatment of women with postmenopausal osteoporosis at high risk for fracture. This study evaluated real-world treatment patterns for patients new to abaloparatide, regardless of osteoporosis treatment history.

Methods

Data for patients with ≥ 1 prescription for abaloparatide were collected retrospectively from six academic and clinical practice settings across the US.

Results

A total of 173 patients were enrolled (mean [SD] age, 69.8 [7.4] years). At the time of abaloparatide treatment initiation, 78.6% had received other osteoporosis medications. Mean (SD) time from discontinuation of osteoporosis medications prior to initiation of abaloparatide was 1.7 (3.2) years. Twenty-four months of follow-up data from the initiation date of abaloparatide was collected from 94.0% of patients and 6.0% of patients had 12–24 months of follow-up. During the follow-up period, 96.0% of patients had at least one visit for osteoporosis management and 55.5% had access to a medication support program. The median duration of therapy was 18.6 months and 105/162 (64.8%) completed abaloparatide treatment as prescribed. The most common reasons for treatment discontinuation were financial (31.2%) and tolerability (22.8%). Following completion of a course of treatment with abaloparatide, 82/162 (50.6%) patients transitioned to another osteoporosis medication. The median time between abaloparatide treatment course completion and the initiation of follow-on medication was 21 days.

Conclusion

Most patients completed treatment with abaloparatide as prescribed, and over half continued with an antiresorptive agent. This favorable conduct may be the result of regular follow-up visits and accessibility to both medication and patient support services.

LeBoff MS, Greenspan SL, Insogna KL, Lewiecki EM, Saag KG, Singer AJ, Siris ES (2022) The clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int 33(10):2049–2102. https://doi.org/10.1007/s00198-021-05900-yCrossRefPubMedPubMedCentral

Bone Health and Osteoporosis Foundation. 54 Million Americans Affected by Osteoporosis and Low Bone Mass. June 2, 2014. Accessed November 21, 2022. https://www.bonehealthandosteoporosis.org/2014/06/02/54-million-americans-affected-by-osteoporosis-and-low-bone-mass/

Gold T, Williams SA, Weiss RJ, Wang Y, Watkins C, Carroll J, Middleton C, Silverman S (2019) Impact of fractures on quality of life in patients with osteoporosis: a US cross-sectional survey. J Drug Assess 8(1):175–183. https://doi.org/10.1080/21556660.2019.1677674CrossRefPubMedPubMedCentral

Hansen D, Pelizzari P, Pyenson B. Medicare cost of osteoporotic fractures - 2021 updated report. The clinical and cost burden of fractures associated with osteoporosis. Milliman Research Report. March 2021. Accessed July 19, 2023. https://www.milliman.com/en/insight/-/media/milliman/pdfs/2021-articles/3-30-21-Medicare-Cost-Osteoporotic-Fractures.ashx

Williams SA, Daigle SG, Weiss R, Wang Y, Arora T, Curtis JR (2021) Economic burden of osteoporosis-related fractures in the US Medicare population. Ann Pharmacother 55(7):821–829. https://doi.org/10.1177/1060028020970518CrossRefPubMed

Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, Harris ST, Hurley DL, Kelly J, Lewiecki EM, Pessah-Pollack R, McClung M, Wimalawansa WNB (2020) American association of clinical endocrinologists/american college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis—2020 update. Endocr Pract 26(Suppl 1):1–46. https://doi.org/10.4158/gl-2020-0524supplCrossRefPubMed

Arceo-Mendoza RM, Camacho PM (2021) Postmenopausal osteoporosis: latest guidelines. Endocrinol Metab Clin North Am 50(2):167–178CrossRefPubMed

Diffenderfer BW, Wang Y, Pearman L, Pyrih N, Williams SA (2023) Real-world management of patients with osteoporosis at very high risk for fracture. J Am Acad Orthop Surg 31(6):e327–e335CrossRefPubMed

Modi A, Sen S, Adachi JD, Adami S, Cortet B, Cooper AL, Geusens P, Mellström D, Weaver J, van den Burgh JP, Nguyen AM, Sajjan S, MUSIC-OS Study Group (2016) Gastrointestinal symptoms and association with medication use patterns, adherence, treatment satisfaction, quality of life, and resource use in osteoporosis: baseline results of the MUSIC-OS study. Osteoporos Int 27(3):1227–1238. https://doi.org/10.1007/s00198-015-3388-3CrossRefPubMed

10.

Barrett-Connor E, Wade SW, Do TP, Satram-Hoang S, Stewart R, Gao G, Macarios D (2012) Treatment satisfaction and persistence among postmenopausal women on osteoporosis medications: 12-month results from POSSIBLE US™. Osteoporos Int 23(2):733–741. https://doi.org/10.1007/s00198-011-1620-3CrossRefPubMed

11.

Siris ES, Selby PL, Saag KG, Borgström F, Herings RM, Silverman SL (2009) Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 122(2 Suppl):S3-13. https://doi.org/10.1016/j.amjmed.2008.12.002CrossRefPubMed

12.

Beaudart C, Silverman S, Gold DT, Williams SA, Weiss R, Hiligsmann M (2022) A qualitative study to assess US patient preferences between new transdermal system and injectable anabolic therapies for osteoporosis treatment. Arch Osteoporos 17(1):57. https://doi.org/10.1007/s11657-022-01075-zCrossRefPubMedPubMedCentral

13.

Lewiecki EM, Leader D, Weiss R, Williams SA (2019) Challenges in osteoporosis awareness and management: results from a survey of US postmenopausal women. J Drug Assess 8(1):25–31. https://doi.org/10.1080/21556660.2019.1579728CrossRefPubMedPubMedCentral

14.

Tymlos. Prescribing information. Radius Health Inc; 2017. Revised June 2023. Accessed November 16, 2023. https://radiuspharm.com/wp-content/uploads/tymlos/tymlos-prescribing-information.pdf

15.

Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CAF, Hu M-Y, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C, ACTIVE Study Investigators (2016) Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 316(7):722–733. https://doi.org/10.1001/jama.2016.11136CrossRefPubMed

16.

Cosman F, Cooper C, Wang Y, Mitlak B, Varughese S, Williams SA (2022) Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: a US administrative claims database study. Osteoporos Int 33(8):1703–1714. https://doi.org/10.1007/s00198-022-06413-yCrossRefPubMedPubMedCentral

17.

Gold DT, Weiss R, Beckett T, Deal C, Epstein RS, James AL, Kernaghan JM, Mohseni M, Spiegel M, Vokes T, Roberts J, Bailey T, Wang Y, Williams SA (2021) Abaloparatide real-world patient experience study. JBMR Plus 5(3):e10457. https://doi.org/10.1002/jbm4.10457CrossRefPubMedPubMedCentral

18.

Durden E, Pinto L, Lopez-Gonzalez L, Juneau P, Barron R (2017) Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States. Arch Osteoporos 12(1):22. https://doi.org/10.1007/s11657-0170316-5CrossRefPubMedPubMedCentral

19.

Cheng L-I, Durden E, Limone B, Radbill L, Juneau PL, Spangler L, Mirza FM, Stolshek BS (2015) Persistance and compliance with osteroporosis therapies among women in a commercially insured population in the United States. J Manag Care Spec Pharm 21(9):824–833a. https://doi.org/10.18553/jmcp.2015.21.9.824CrossRefPubMed

20.

Halpern R, Becker L, Iqbal SU, Kazis LE, Macarios D, Badamgarav E (2011) The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis. J Manag Care Pharm 17(1):25–39. https://doi.org/10.18553/jmcp.2011.17.1.25CrossRefPubMed

21.

Ross S, Samuels E, Gairy K, Iqbal S, Badamgarav E, Siris E (2011) A meta-analysis of osteoporotic fracture risk with medication nonadherence. Value Health 14(4):571–581. https://doi.org/10.1016/j.jval.2010.11.010CrossRefPubMed

22.

Keshishian A, Boytsov N, Burge R, Krohn K, Lombard L, Zhang X, Xie L, Baser O (2017) Examining the effect of medication adherence on risk of subsequent fracture among women with a fragility fracture in the U.S. Medicare population. J Manag Care Spec Pharm 23(11):1178–1190. https://doi.org/10.18553/jmcp.2017.17054CrossRefPubMed

23.

Modi A, Siris ES, Tang J, Sen S (2015) Cost and consequences of noncompliance with osteoporosis treatment among women initiating therapy. Curr Med Res Opin 31(4):757–765. https://doi.org/10.1185/03007995.2015.1016605CrossRefPubMed

Title: Treatment patterns in women with postmenopausal osteoporosis using abaloparatide: a real-world observational study
Authors: Deborah T. Gold
Tammy Beckett
Chad Deal
Andrew L. James
Mahshid Mohseni
Abigail McMillan
Tom Bailey
Leny Pearman
John Caminis
Yamei Wang
Setareh A. Williams
Jacqueline M. Kernaghan
Publication date: 24-04-2024
Publisher: Springer London
Keywords: Osteoporosis
Osteoporosis
Published in: Osteoporosis International
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-024-07070-z

At a glance: The STEP trials

Springer Medicine

Treatment patterns in women with postmenopausal osteoporosis using abaloparatide: a real-world observational study

Abstract

Summary

Purpose

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Summary

Purpose

Methods

Results

Conclusion

Please log in to get access to this content